Voyager Therapeutics (VYGR) Free Cash Flow (2014 - 2026)

Voyager Therapeutics has disclosed Free Cash Flow across 13 years of filings, most recently posting -$33.4 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$33.4 million, up 13.28% year-over-year; the trailing twelve-month figure through Mar 2026 was -$129.9 million (down 13.98% YoY), and the FY2025 annual result was -$135.1 million, down 617.24% from the prior year.
• Free Cash Flow came in at -$33.4 million for Q1 2026 at Voyager Therapeutics, down from -$30.9 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $123.1 million in Q1 2023 to a low of -$38.6 million in Q1 2025.
• The 5-year median for Free Cash Flow is -$21.8 million (2023), against an average of -$7.5 million.
• Across the five-year window, Free Cash Flow soared 260.47% in 2022 and tumbled 1491.54% in 2024, its largest moves.
• Voyager Therapeutics' Free Cash Flow stood at -$13.2 million in 2022, then slumped by 86.04% to -$24.5 million in 2023, then jumped by 40.1% to -$14.7 million in 2024, then plunged by 110.36% to -$30.9 million in 2025, then declined by 8.24% to -$33.4 million in 2026.
• The last three Free Cash Flow figures came in at -$33.4 million (Q1 2026), -$30.9 million (Q4 2025), and -$31.3 million (Q3 2025), per Business Quant data.